Search

Serelaxin

human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come

Finafloxacin

Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

Poloxamer 407

Poloxamer 407 is used as an emulsifying agent and solubilizing agent in cosmetic and personal products such as contact lens cleaning solutions. … It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature.

Transcrocetinate

Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.

Icotrokinra

Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

Arzoxifene

Picric acid

Used as antiseptic, astringent, and stimulant for epitheliazation.

Cresol

Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal pain, and/or vomiting. … At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.

Umbralisib

Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … [A229668] On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results

Zapomeran

[L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585] … Self-amplification allows for the use of lower doses while providing higher immunogenicity compared to a conventional mRNA COVID-19 vaccine.